Research programme: small-molecule anti-inflammatory therapy - Eidogen-Sertanty/Kalypsys
Alternative Names: anti-inflammatory agents - Eidogen Sertanty/KalypsysLatest Information Update: 16 Jul 2016
At a glance
- Originator Eidogen-Sertanty; Kalypsys
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 29 Dec 2005 Preclinical trials in Inflammation in USA (unspecified route)